Synonyms: APD-334 | APD334 | APD334-003 | compound 4 [PMID: 25516790] | Velsipity®
etrasimod is an approved drug (FDA (2023), EMA (2024))
Compound class:
Synthetic organic
Comment: Etrasimod (APD334) is a centrally available, selective S1P1 receptor agonist [2]. APD334 is being investigated for clinical efficacy as an immunosuppressant for the treatment of autoimmune diseases.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Etrasimod (APD334) was advanced to clinical trial in patients with moderately to severely active ulcerative colitis (see NCT02536404). It was approved for this indication by the FDA in October 2023 [4]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT02536404 | Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis | Phase 2 Interventional | Arena Pharmaceuticals |